ADC Therapeutics SA (ADCT) Financial Statements
ADC Therapeutics SA (ADCT) reported trailing twelve-month revenue of $79.6M (up 3.0% year on year) and net income of -$96.9M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$102.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 183.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26. Results for the next quarter were released 13 Oct; these figures move once the 10-Q is filed.
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Revenue | 69.6 | 70.8 | 81.4 | 79.6 | |
| Gross profit | 67.0 | 64.9 | 75.6 | — | |
| Research & development | 127.1 | 109.6 | 104.0 | 82.2 | |
| Operating income | -166.0 | -130.7 | -121.5 | -99.5 | |
| Pre-tax income | -195.4 | -156.1 | -141.6 | -97.3 | |
| Income tax | 39.1 | 0.2 | 1.0 | -0.4 | |
| Net income | -240.1 | -157.8 | -142.6 | -96.9 | |
| Diluted EPS ($) | -2.94 | -1.62 | -1.12 | -0.62 | |
| Diluted shares (mn) | 81.7 | 97.2 | 127.1 | — |
USD millions · SEC XBRL
ADC Therapeutics SA — questions
- What is ADC Therapeutics SA's revenue?
- $79.6M over the twelve months to 2026-06-30, up 3.0% year on year, from its 10-Q and 10-K filings.
- What is ADC Therapeutics SA's net income?
- -$96.9M over the twelve months to 2026-06-30.
- What is ADC Therapeutics SA's free cash flow?
- -$102.3M over the twelve months to 2026-06-30.
- What are ADC Therapeutics SA's diluted earnings per share?
- $-0.62 over the twelve months to 2026-06-30.
Every figure on this page comes from ADC Therapeutics SA's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.